The investigation, known as the Oslo Schizophrenia Recovery Study, or OSR, was designed to answer two deceptively simple questions. First, how does resilience change over time in people with first-episode schizophrenia compared with healthy peers? Second, do resilience trajectories differ between patients who meet strict criteria for clinical recovery and those who do not? To find out, the team recruited 28 individuals experiencing their first episode of a schizophrenia-spectrum psychosis and 28 healthy controls matched one-to-one by gender, age, and education. Participants were assessed repeatedly, with twelve clinical evaluations spread across a decade, an unusually intensive design for this field.

Resilience, a concept psychologists sometimes call ordinary magic, refers to the capacity to adapt well in the face of adversity, trauma, or significant stress. It is best understood not as a fixed personality trait but as a dynamic process spanning biological, psychological, and social systems. The researchers measured it using the Connor-Davidson Resilience Scale, a 25-item questionnaire that asks respondents to rate statements such as I am able to adapt to change and I tend to bounce back after illness or hardship. Social and role functioning were tracked with the Global Functioning Scales, which separately capture the quality of peer and family relationships and performance in work, school, or homemaking.

Clinical recovery was defined rigorously, following operational criteria developed by Liberman and colleagues. Patients had to achieve remission of core psychotic symptoms, with scores below a defined threshold on key items of the Positive and Negative Syndrome Scale covering delusions, hallucinations, disorganized thinking, blunted affect, and social withdrawal. They also needed adequate functioning, meaning at least part-time paid work or schooling, independent living, and age-appropriate social activity, and this state had to persist for two full years. By the ten-year mark, half of the original patient group had met these demanding criteria.

Statistically, the team relied on linear mixed-effects growth models, a multilevel modeling approach well suited to repeated-measures data. Rather than discarding participants with missing observations, these models use all available data, a critical advantage in a small longitudinal sample. Candidate models were compared using the small-sample corrected Akaike Information Criterion, which penalizes unnecessary complexity, and parameters were estimated by maximum likelihood under a missing-at-random assumption. For the recovery comparison, the researchers also fitted piecewise models that allowed separate slopes before and after a breakpoint, testing breakpoints at six months, one year, and two years to check that the results did not hinge on an arbitrary choice.

The retention figures alone are noteworthy. Longitudinal studies in psychosis routinely lose large fractions of their samples, but the OSR study kept 79 percent of participants at ten years, with all 28 patients completing the first three follow-up assessments. The six who dropped out tended to have more severe positive and general symptoms at baseline, prompting a sensitivity analysis that adjusted for baseline symptom scores; the estimated resilience trajectories were essentially unchanged. This combination of high retention and repeated annual measurement is what allowed the researchers to trace individual trajectories with a precision that cross-sectional snapshots cannot match.

So what did the decade reveal? In the patient group as a whole, resilience rose steadily over time, while the matched healthy controls remained comparatively stable across the ten years. The model-estimated increase in the patients was large enough that their average resilience approached the control group’s level by the end of the study, although the formal statistical test for a difference in trajectories between the two groups did not reach significance, and the authors are careful to note that support for differential trajectories was limited. Individual paths varied widely in both groups, with some participants showing marked gains and others flat courses, underscoring that resilience is far from uniform even among people facing similar diagnoses.

The sharpest signal emerged when the researchers split the patient group by recovery status. Baseline resilience scores did not differ significantly between those who would later recover and those who would not, meaning the two subgroups started from comparable points. But their paths then diverged dramatically. Recovered patients showed a steep, rapid rise in resilience during the first year after baseline, followed by more gradual gains, a pattern the authors liken to the rapid-recovery trajectory described in the broader resilience literature by George Bonanno. Non-recovered patients, including some in symptom remission, improved only modestly and gradually, and their resilience remained clearly lower at study completion. Sensitivity analyses confirmed the one-year breakpoint fit the data best.

The authors offer several tentative explanations for the early surge among those who recover. It could reflect spontaneous remission, an especially effective response to antipsychotic medication, or ongoing neural maturation in this young cohort that limits how deeply the illness disrupts premorbid resilience. Social factors likely sustain the gains over time: at ten years, 93 percent of clinically recovered participants were employed and more than half were in intimate relationships, and prior research suggests close relationships and income from regular work both feed back into resilient functioning. Norway’s relatively open public attitudes toward mental illness may also have helped, since the ecological environment is considered a crucial component of the resilience process.

Importantly, the study cannot establish causality. Because resilience was first measured only after illness onset, the researchers cannot disentangle pre-existing resilience from adaptations to psychosis, treatment, and life context, and self-report measures may be influenced by insight, symptom severity, or the favorable self-views of those who have recovered. The small sample of 28 patients is an obvious constraint. Still, the practical implication is compelling: the greatest resilience gains among future recoverers occurred during the first year of treatment, marking that period as a potential window of opportunity. Interventions such as individual resiliency training, which builds well-being and social functioning by focusing on a patient’s strengths, might usefully supplement standard care for less resilient patients, potentially reducing their vulnerability to future episodes and improving long-term outcomes.

Subject of Research: Longitudinal trajectories of psychological resilience in clinical recovery from first-episode schizophrenia

Article Title: Resilience and clinical recovery in first-episode schizophrenia: a 10-year longitudinal study of clinically recovered, non-recovered, and healthy control participants

Article References: Torgalsbøen, A.-K., Mohn, C., Larøi, F., & Czajkowski, N. (2026). Resilience and clinical recovery in first-episode schizophrenia: a 10-year longitudinal study of clinically recovered, non-recovered, and healthy control participants. Frontiers in Psychiatry, 17, Article 1813256. https://doi.org/10.3389/fpsyt.2026.1813256

Image Credits: AI Generated

DOI: 10.3389/fpsyt.2026.1813256

Keywords: schizophrenia, first-episode psychosis, resilience, clinical recovery, longitudinal study, Oslo Schizophrenia Recovery Study, Connor-Davidson Resilience Scale, psychiatry, mental health, psychosis, recovery trajectories, Norway